medline.ch Onkologie Urologische Tumoren

	Accurate focal-plane selection is crucial for artificial intelligence assessment of three-dimensional urine cytology specimens for bladder cancer screening and surveillance. Cancer Cytopathol Sayegh Y, McNutt B, Le MK, Liao IC, Yao K, Ng C, Kohsar A, Shou D, Yu M, Jin Y, Vaickus LJ, Liu X, VandenBussche CJ, Harvey SE, Levy JJ. PMID: 42363782 [PubMed - in process]
	Long-term trends in the burden of prostate cancer in the United States from 1990 to 2021: A detailed analysis based on the Global Burden of Disease Study 2021. Medicine (Baltimore) Guo G, Zhang L, Zhang W, Lin J, Lin H, Li X, Huang P. PMID: 42363557 [PubMed - in process]
	Exploring shared decision-making in prostate cancer screening within primary health care settings in Portugal: a cross-sectional study. BMC Prim Care Oliveira B, Lopes L, de Oliveira Branco S, Oliveira S, Granja A, Gonçalves F, Pinto J, Silva M, Coelho S, Fraga A, Teves F. PMID: 42363103 [PubMed - as supplied by publisher]
	Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management. Urol Clin North Am Hargis P, Baker H, Wiesen B, Kukreja J. PMID: 42362308 [PubMed - in process]
	Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care. Urol Clin North Am Jiang T, Zhao CC, Liao JC. PMID: 42362307 [PubMed - in process]
	Economic Considerations in the Management of Superficial Bladder Cancer. Urol Clin North Am Gupta VK, Joyce DD, Wymer KM, Sharma V. PMID: 42362306 [PubMed - in process]
	Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care. Urol Clin North Am Fu MZ, Sykes J, Pfail J, Packiam VT. PMID: 42362305 [PubMed - in process]
	Impact of Social and Structural Determinants of Health on Bladder Cancer Outcomes: Focus on Non-Muscle-Invasive Disease. Urol Clin North Am Zhu S, Washington SL 3rd, Sekar R, Chu CE. PMID: 42362304 [PubMed - in process]
	Management of High-Risk Non-Muscle-Invasive Bladder Cancer. Urol Clin North Am Tallman JE, Goh AC. PMID: 42362302 [PubMed - in process]
	Molecular and Genetic Insights for Personalized Treatment of Non-Muscle-Invasive Bladder Cancer. Urol Clin North Am Nolazco JI, Yim K, Salari K. PMID: 42362301 [PubMed - in process]
	Emerging Intravesical Therapies for Non-Muscle-Invasive Bladder Cancer. Urol Clin North Am Wang B, Isali I, Calaway A, Bukavina L. PMID: 42362299 [PubMed - in process]
	Role of Enhanced Imaging in Superficial Bladder Cancer Management. Urol Clin North Am Chou WH, Lechner A, Liu JJ. PMID: 42362298 [PubMed - in process]
	Advances in Diagnosis of Non-Muscle-Invasive Bladder Cancer: A Review. Urol Clin North Am Higgins MI, Rivera Lopez CA, Lokeshwar SD, Patel SH. PMID: 42362296 [PubMed - in process]
	Epidemiology and Risk Factors for Non-Muscle-Invasive Bladder Cancer: Insights into Prevalence, Risk Stratification, and Implications for Early Diagnosis. Urol Clin North Am Akinsola O, Bharadwaj M, Psutka SP. PMID: 42362295 [PubMed - in process]
	Extended versus Standard Lymph Node Dissection at the Time of Radical Cystectomy for Bladder Cancer. Urology Almohtasib J, Scire E, Kaul S, Fleishman A, Chang P, Wagner A, Bellmunt J, Korets R, Olumi AF, Gershman B. PMID: 42361989 [PubMed - as supplied by publisher]
	The role of acrylamide exposure in prostate cancer progression: An integrated analysis based on network toxicology and experimental validation. Ecotoxicol Environ Saf Chen JY, Lin TT, Zheng WC, Yan ZH, Lin B, Liu MX, Wei Y, Xue XY, Zheng QS, Ke ZB, Xu N. PMID: 42361668 [PubMed - as supplied by publisher]
	Association between L-Î±-glycerylphosphorylcholine use and risk of kidney cancer: A nationwide representative retrospective cohort study. Cancer Epidemiol Park YJ, Yu J, Kang JH, Park SJ, Jeong S, Lee G, Shin HY, Park SM. PMID: 42361543 [PubMed - as supplied by publisher]
	AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial. Clin Cancer Res Medina S, Tokuyama N, Putcha V, Pathak T, Fu P, Thomas H, Subhash VV, Yip S, Lin HM, Horvath LG, Kench JG, Zhang A, Stockler MR, Joshua AM, Azad A, Oakes SR, Davis ID, Sweeney CJ, Madabhushi A. PMID: 42360803 [PubMed - as supplied by publisher]
	Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment Landscape. Oncol Ther Rini BI, Garmezy B. PMID: 42360585 [PubMed - as supplied by publisher]
	Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy. Cancer Biol Ther Staton A, Abel M, Figg WD. PMID: 42359636 [PubMed - indexed for MEDLINE]

Artikel 1 - 20 / 179423

Seite 1 von 8972

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung